KYMR

Conviction 80HealthcareScan · Mon, Aug 10, 2026

Bullish belt hold

KYMR$108.59+1.00%

ResistanceSupportVol 14Insider sell

Vol MA14 527.39K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Kymera Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kymeratx.com ↗

Price108.59

Change+1.00%

Gap-1.30%

Rel volume0.68×

Avg volume538.84K

Avg $ vol58.63M

SMA 20108.81

SMA 50101.04

SMA 20083.53

Price vs 50+7.48%

Price vs 200+30.00%

MA stackbullish

50/200 cross—

Supertrendup · 96.68

RSI (14)53

MACD hist-0.75

MACD cross—

Stoch %K / %D62 / 50

ADX (14)26

+DI / −DI23 / 17

RSI divergence—

MACD divergence—

ATR %+4.40%

ADR %3.97%

52w high119.35

52w low37.68

From 52w high-9.02%

Above 52w low+188.19%

New 52w highNo

SqueezeOff

Bollinger width14.52%

%B0.49

Donchian pos44.66%

Donchian high119.83

Donchian low99.52

AVWAP (52w high)112.08

vs AVWAP high-3.12%

AVWAP (52w low)78.44

vs AVWAP low+38.44%

OBV trendFlat

Chaikin MF (20)-0.01

Today vs 20d0.68×

Avg vol (14d)527.39K

Avg vol (20d)538.84K

Avg $ vol (20d)58.63M

Market cap—

RS 3m (vs SPY)+21.35%

RS 6m (vs SPY)+27.47%

RS line new highNo

Trend template8/8

Technical rank76.5

1 week+8.25%

1 month-9.02%

3 months+26.15%

6 months+36.44%

1 year+165.83%

YTD+49.24%

P/E-28.71

P/B5.92

P/S227.94

P/FCF-38.14

EPS-3.69

Div yield—

ROE-20.63%

ROA-18.92%

Debt/Eq—

Current10.34

EV/EBITDA-25.84

Gross margin—

Net margin-794.04%

Rev growth-16.70%

EPS growth-39.08%

Price target131.29

Target upside22.14%

Analyst ratingBuy

Institutional125.14%

Ent. value8.81B

Revenue65M

Net income-61.21M

Gross profit—

Free cash flow-234.34M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out82.26M

Employees253

ListedFri, Aug 21, 2020

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA

Conviction80 / 100

Pattern quality—

Tech rank76.5 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBullish belt hold

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KYMR

All disclosures →

No recent disclosed trades by Congress in KYMR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KYMR · 3 buys · 7 sells

Insider	Side	Shares	Value	Traded	Filed
Rooney Terence Chief Medical Officer · Stock Option (Right to Buy) · 2026-07-27	Grant	76K	—	2026-07-27	2026-07-27
Rooney Terence Chief Medical Officer · Common Stock · 2026-07-27	Grant	38K	—	2026-07-27	2026-07-27
Mainolfi Nello Chief Executive Officer · Common Stock · 2026-07-07	Exercise	50K	$104K	2026-07-07	2026-07-07
Mainolfi Nello Chief Executive Officer · Common Stock · 2026-07-07	Sell	50K	$6.0M	2026-07-07	2026-07-07
Mainolfi Nello Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07	Exercise	45.56K	—	2026-07-07	2026-07-07
Mainolfi Nello Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07	Exercise	4.44K	—	2026-07-07	2026-07-07
Booth Bruce Director · Common Stock · 2026-06-29	Sell	157	$17K	2026-06-29	2026-06-30
Booth Bruce Director · Common Stock · 2026-06-29	Sell	7.83K	$860K	2026-06-29	2026-06-30
Booth Bruce Director · Common Stock · 2026-06-29	Sell	7.6K	$841K	2026-06-29	2026-06-30
Booth Bruce Director · Common Stock · 2026-06-29	Sell	907	$101K	2026-06-29	2026-06-30

SEC filings

EDGAR filings in KYMR · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.